Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib
combined with docetaxel versus docetaxel, administered as first-line treatment, in patients
with unresectable locally recurrent or metastatic breast cancer.